Here Comes the Booming Chinese Biotech Sector
Odd Lots
Contrasting Drug Development: China vs. U.S. Regulatory Dynamics
This chapter explores the differences in drug development regulations between China and the United States, focusing on the advantages of China's quicker patient access through phase zero studies. It also examines the challenges and financial aspects of conducting clinical trials in the U.S., highlighting the disparities in healthcare systems and incentives for medical professionals.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
